AIM: To investigate the effects of different methylenetetrahydrofolate reductase (MTHFR) 677C>T gene polymorphism and hyperhomocysteinemia for the development of renal failure and cardiovascular events, which are controversial. METHODS: We challenged the relationship, if any, of MTHFR 677C>T and MTHFR 1298A>C polymorphisms with renal and heart function. The present article is a reappraisal of these concepts, investigating within a larger population, and including a subgroup of dialysis patients, if the two most common MTHFR polymorphisms, C677T and A1298C, as homozygous, heterozygous or with a compound heterozygous state, show different association with chronic renal failure requiring hemodialysis. MTHFR polymorphism could be a favorable evolutionary factor, i.e., a protective factor for many ominous conditions, like cancer and renal failure. A similar finding was reported in fatty liver disease in which it is suggested that MTHFR polymorphisms could have maintained and maintain their persistence by an heterozygosis advantage mechanism. We studied a total of 630 Italian Caucasian subject aged 54.60 ± 16.35 years, addressing to the increased hazard of hemodialysis, if any, according to the studied MTHFR genetic polymorphisms. RESULTS: A favorable association with normal renal function of MTHFR polymorphisms, and notably of MTHFR C677T is present independently of the negative effects of left ventricular hypertrophy, increased Intra-Renal arterial Resistance and hyperparathyroidism. CONCLUSION: MTHFR gene polymorphisms could have a protective role on renal function as suggested by their lower frequency among our dialysis patients in end-stage renal failure; differently, the association with left ventricular hypertrophy and reduced left ventricular relaxation suggest some type of indirect, or concurrent mechanism.
AIM: To investigate the effects of different methylenetetrahydrofolate reductase (MTHFR) 677C>T gene polymorphism and hyperhomocysteinemia for the development of renal failure and cardiovascular events, which are controversial. METHODS: We challenged the relationship, if any, of MTHFR 677C>T and MTHFR 1298A>C polymorphisms with renal and heart function. The present article is a reappraisal of these concepts, investigating within a larger population, and including a subgroup of dialysis patients, if the two most common MTHFR polymorphisms, C677T and A1298C, as homozygous, heterozygous or with a compound heterozygous state, show different association with chronic renal failure requiring hemodialysis. MTHFR polymorphism could be a favorable evolutionary factor, i.e., a protective factor for many ominous conditions, like cancer and renal failure. A similar finding was reported in fatty liver disease in which it is suggested that MTHFR polymorphisms could have maintained and maintain their persistence by an heterozygosis advantage mechanism. We studied a total of 630 Italian Caucasian subject aged 54.60 ± 16.35 years, addressing to the increased hazard of hemodialysis, if any, according to the studied MTHFR genetic polymorphisms. RESULTS: A favorable association with normal renal function of MTHFR polymorphisms, and notably of MTHFRC677T is present independently of the negative effects of left ventricular hypertrophy, increased Intra-Renal arterial Resistance and hyperparathyroidism. CONCLUSION:MTHFR gene polymorphisms could have a protective role on renal function as suggested by their lower frequency among our dialysis patients in end-stage renal failure; differently, the association with left ventricular hypertrophy and reduced left ventricular relaxation suggest some type of indirect, or concurrent mechanism.
Entities:
Keywords:
Echocardiography; Genetic; Glomerular filtration rate; Homocysteine; Insulin resistance; Left ventricular hypertrophy; Mediterranean diet; Methylenetetrahydrofolate reductase polymorphism; Obesity; Renal function
Authors: I M Rea; D McMaster; J V Woodside; I S Young; G P Archbold; T Linton; S Lennox; H McNulty; D L Harmon; A S Whitehead Journal: Atherosclerosis Date: 2000-03 Impact factor: 5.162
Authors: Jeffrey L Anderson; Ryan C Vanwoerkom; Benjamin D Horne; Tami L Bair; Heidi T May; Donald L Lappé; Joseph B Muhlestein Journal: Am Heart J Date: 2011-08 Impact factor: 4.749
Authors: Martin K Rutter; Peter W F Wilson; Lisa M Sullivan; Caroline S Fox; Ralph B D'Agostino; James B Meigs Journal: Circulation Date: 2008-02-04 Impact factor: 29.690
Authors: Michaela Maurer; Sonja Burri; Stefano de Marchi; Roger Hullin; Michele Martinelli; Paul Mohacsi; Otto M Hess Journal: Int J Cardiol Date: 2009-01-31 Impact factor: 4.164
Authors: Sonia L La'ulu; Mindy L Rawlins; Christine M Pfeiffer; Mindy Zhang; William L Roberts Journal: Am J Clin Pathol Date: 2008-12 Impact factor: 2.493
Authors: Quanhe Yang; Lynn Bailey; Robert Clarke; W Dana Flanders; Tiebin Liu; Ajay Yesupriya; Muin J Khoury; Jan M Friedman Journal: Am J Clin Nutr Date: 2012-04-04 Impact factor: 7.045
Authors: Giuseppe Cianciolo; Antonio De Pascalis; Luca Di Lullo; Claudio Ronco; Chiara Zannini; Gaetano La Manna Journal: Cardiorenal Med Date: 2017-06-21 Impact factor: 2.041
Authors: Francesca M Trovato; Joshua M Tognarelli; Mary Me Crossey; Daniela Catalano; Simon D Taylor-Robinson; Guglielmo M Trovato Journal: World J Hepatol Date: 2015-11-18